Provectus Biopharmaceuticals Converts $542.5K Director Fees to Preferred Stock Amid Cash Crunch
PVCT sits 76% above its 52-week low of $0.038 on elevated volume (1.8× avg).
Summary
Provectus Biopharmaceuticals is converting $542,500 in accrued director fees into convertible preferred stock, signaling significant cash constraints and potential dilution for shareholders.
Key Events · Financing and Capital Events · PVCT
-
Director Compensation in Stock
The Board approved converting $542,500 in accrued director fees, owed through June 30, 2026, into Series D-1 Preferred Stock at a price of $2.862 per share.
-
Potential Dilution
The Preferred Stock is convertible into 1,895,540 shares of common stock, representing a notable percentage of the company's current market capitalization.
-
Indication of Cash Constraints
Paying directors with stock instead of cash highlights the company's critically low cash position, as previously disclosed in its May 14, 2026 10-Q, and reinforces its "going concern" warning.
Analysis · PVCT · Life Sciences
This filing reveals that Provectus Biopharmaceuticals is converting over half a million dollars in accrued director fees into preferred stock, which is convertible into common shares. This move, representing a significant portion of the company's market capitalization, strongly indicates severe cash constraints. For a company already under a "going concern" warning and reporting critically low cash, paying its board members with stock rather than cash is a clear signal of financial distress and further potential dilution for existing shareholders. This event underscores the challenges the company faces in maintaining liquidity and funding operations.
At the time of this filing, PVCT was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $29.2M. The 52-week trading range was $0.04 to $0.11. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.